Cancer cell sensitivity to bortezomib is associated with survivin expression and p53 status but not cancer cell types
Open Access
- 22 January 2010
- journal article
- research article
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 29 (1) , 8
Abstract
Survivin is known playing a role in drug resistance. However, its role in bortezomib-mediated inhibition of growth and induction of apoptosis is unclear. There are conflicting reports for the effect of bortezomib on survivin expression, which lacks of a plausible explanation. Methods: In this study, we tested cancer cells with both p53 wild type and mutant/null background for the relationship of bortezomib resistance with survivin expression and p53 status using MTT assay, flow cytometry, DNA fragmentation, caspase activation, western blots and RNAi technology.Keywords
This publication has 50 references indexed in Scilit:
- Generation of a Novel Transgenic Mouse Model for Bioluminescent Monitoring of Survivin Gene Activity in Vivo at Various Pathophysiological ProcessesThe American Journal of Pathology, 2010
- Interactions of the Hdm2/p53 and Proteasome Pathways May Enhance the Antitumor Activity of BortezomibClinical Cancer Research, 2009
- Randomized Phase II Trial of Docetaxel Plus Cetuximab or Docetaxel Plus Bortezomib in Patients With Advanced Non–Small-Cell Lung Cancer and a Performance Status of 2: CALGB 30402Journal of Clinical Oncology, 2009
- BortezomibDrugs, 2009
- Every Single Cell Clones from Cancer Cell Lines Growing Tumors In Vivo May Not Invalidate the Cancer Stem Cell ConceptMolecules and Cells, 2009
- Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms MacroglobulinemiaLeukemia & Lymphoma, 2009
- Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphomaMolecular Cancer, 2008
- Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation studyBritish Journal of Cancer, 2008
- Targeting survivin in cancer therapyExpert Opinion on Therapeutic Targets, 2008
- Forced Expression of Survivin-2B Abrogates Mitotic Cells and Induces Mitochondria-dependent Apoptosis by Blockade of Tubulin Polymerization and Modulation of Bcl-2, Bax, and SurvivinJournal of Biological Chemistry, 2007